Trial · NCT03053115
Combined Replacement Therapy With Levothyroxine and Liothyronine in Thyroidectomized Patients
NCT03053115, Phase 2, Phase 3, Completed, Azienda USL Modena
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Combined Replacement Therapy With Levothyroxine and Liothyronine in Thyroidectomized Patients. Trials, record NCT03053115. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03053115
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Combined Replacement Therapy With Levothyroxine and Liothyronine in Thyroidectomized Patients
- NCT number
- NCT03053115
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 160 participants, actual
- Lead sponsor
- Azienda USL Modena
- Conditions
- Hypothyroidism
- Interventions
- Liothyronine, Levothyroxin, Placebos
- First posted
- 2017-02-14
- Last updated
- 2023-04-21
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | change from baseline SHBG serum levels at 12 and 24 weeks (nmol/L) | baseline and then repeated at 12 weeks and 24 weeks | change from baseline SHBG serum levels at 12 and 24 weeks (nmol/L) |
| Secondary | BMI (kg/m2) | baseline and then repeated at 6, 12 weeks and 24 weeks | body mass index |
| Secondary | quality of life changes | baseline and then repeated at 12 weeks and 24 weeks | score at validated questionnaires |
| Secondary | change from baseline TSH serum levels at 12 and 24 weeks (microIU/ml) | baseline and then repeated at 12 weeks and 24 weeks | change from baseline TSH serum levels at 12 and 24 weeks (microIU/ml) |
| Secondary | change from baseline free triiodothyronine (fT3) serum levels at 12 and 24 weeks (pmol/L) | baseline and then repeated at 12 weeks and 24 weeks | change from baseline free triiodothyronine (fT3) serum levels at 12 and 24 weeks (pmol/L) |
| Secondary | change from baseline free levothyroxine (fT4) serum levels at 12 and 24 weeks (pmol/L) | baseline and then repeated at 12 weeks and 24 weeks | change from baseline free levothyroxine (fT4) serum levels at 12 and 24 weeks (pmol/L) |
| Secondary | change from baseline total cholesterol serum levels at 12 and 24 weeks (mg/dl) | baseline and then repeated at 12 weeks and 24 weeks | change from baseline total cholesterol serum levels at 12 and 24 weeks (mg/dl) |
| Secondary | change from baseline HDL cholesterol serum levels at 12 and 24 weeks (mg/dl) | baseline and then repeated at 12 weeks and 24 weeks | change from baseline HDL cholesterol serum levels at 12 and 24 weeks (mg/dl) |
| Secondary | change from baseline triglycerides serum levels at 12 and 24 weeks (mg/dl) | baseline and then repeated at 12 weeks and 24 weeks | change from baseline triglycerides serum levels at 12 and 24 weeks (mg/dl) |
| Secondary | change from baseline C-terminal telopeptide of type 1 collagen at 12 and 24 weeks (ng/dl) | baseline and then repeated at 12 weeks and 24 weeks | change from baseline C-terminal telopeptide of type 1 collagen at 12 and 24 weeks (ng/dl) |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03053115
GET https://conductscience.org/api/trials/v1/NCT03053115/registered